{"created":"2023-05-15T16:38:02.969317+00:00","id":11538,"links":{},"metadata":{"_buckets":{"deposit":"d9891f07-768e-4d58-9046-b11335784e7f"},"_deposit":{"created_by":2,"id":"11538","owners":[2],"pid":{"revision_id":0,"type":"depid","value":"11538"},"status":"published"},"_oai":{"id":"oai:nagasaki-u.repo.nii.ac.jp:00011538","sets":["29:30"]},"author_link":["44192","44195","44185","44196","44188","44194","44189","44193","44197","44190","44186","44191","44187"],"item_2_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2012-02","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"2","bibliographicPageEnd":"213","bibliographicPageStart":"209","bibliographicVolumeNumber":"95","bibliographic_titles":[{"bibliographic_title":"International Journal of Hematology"}]}]},"item_2_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"The T315I BCR-ABL mutation in chronic myelogenous leukemia (CML) patients is responsible for up to 20% of all clinically observed resistance. This mutation confers resistance not only to imatinib, but also to second-generation BCR-ABL tyrosine kinases, such as nilotinib and dasatinib. A number of strategies have been implemented to overcome this resistance, but allogeneic stem cell transplantation remains the only established therapeutic option for a cure. A 61-year-old male was diagnosed with Philadelphia chromosome-positive chronic-phase CML in 2002. He was initially treated with imatinib and complete cytogenetic response (CCyR) was achieved 12 months later. However, after 18 months, a loss of CCyR was observed and a molecular study at 24 months revealed a T315I mutation of the BCR-ABL gene. At 30 months, imatinib/interferon-alfa (IFNα) combination therapy was initiated in an effort to overcome the resistance. Thirty months later, he re-achieved CCyR, and the T315I BCR-ABL mutation disappeared at 51 months. To our knowledge, this is the first case report showing the effectiveness of imatinib/IFNα combination therapy for CML patients bearing the T315I BCR-ABL mutation.","subitem_description_type":"Abstract"}]},"item_2_description_63":{"attribute_name":"引用","attribute_value_mlt":[{"subitem_description":"International Journal of Hematology, 95(2), pp.209-213; 2012","subitem_description_type":"Other"}]},"item_2_relation_12":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.1007/s12185-012-1005-1","subitem_relation_type_select":"DOI"}}]},"item_2_rights_13":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"© The Japanese Society of Hematology 2012"},{"subitem_rights":"The original publication is available at www.springerlink.com"}]},"item_2_source_id_10":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AA10797094","subitem_source_identifier_type":"NCID"}]},"item_2_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"09255710","subitem_source_identifier_type":"ISSN"}]},"item_2_source_id_8":{"attribute_name":"EISSN","attribute_value_mlt":[{"subitem_source_identifier":"18653774","subitem_source_identifier_type":"ISSN"}]},"item_2_version_type_16":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Itonaga, Hidehiro"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Tsushima, Hideki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Hata, Tomoko"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Matsuo, Emi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Imanishi, Daisuke"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Imaizumi, Yoshitaka"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kawaguchi, Yasuhisa"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Fukushima, Takuya"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Doi, Yuko"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Mori, Sayaka"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kamihira, Shimeru"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Tomonaga, Masao"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Miyazaki, Yasushi"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-12-22"}],"displaytype":"detail","filename":"IJH95_209.pdf","filesize":[{"value":"413.7 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"IJH95_209.pdf","url":"https://nagasaki-u.repo.nii.ac.jp/record/11538/files/IJH95_209.pdf"},"version_id":"e7d69f65-7b03-404e-9547-25ff9e869dc9"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Chronic myelogenous leukemia","subitem_subject_scheme":"Other"},{"subitem_subject":"Imatinib","subitem_subject_scheme":"Other"},{"subitem_subject":"Interferon","subitem_subject_scheme":"Other"},{"subitem_subject":"T315I","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa"}]},"item_type_id":"2","owner":"2","path":["30"],"pubdate":{"attribute_name":"公開日","attribute_value":"2013-03-01"},"publish_date":"2013-03-01","publish_status":"0","recid":"11538","relation_version_is_last":true,"title":["Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa"],"weko_creator_id":"2","weko_shared_id":-1},"updated":"2023-05-16T01:11:48.395540+00:00"}